Technology Bundle ID
TAB-3466

Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders

Applications
Linked ID
E-116-2016-0
Lead Inventors
Craig Thomas (NCATS)
Co-Inventors
Carlos Zarate (NIMH)
Panos Zanos (University of Maryland)
Patrick Morris (NCATS)
Ruin Moaddel (NIA)
Todd Gould (University of Maryland)
ICs
This technology includes a method for synthesizing the ketamine analogs (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine that may be useful for the treatment of pain, depression, anxiety, and related disorders. The drug ketamine was first used as an anesthetic but was found to be an effective treatment in a range of conditions, including paint, treatment-resistant bipolar depression, and other anxiety-related disorders. However, the routine use of ketamine is hindered by unwanted side effects, including the potential for abuse. Ketamine analogs have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects.
Commercial Applications
Further clinical work with these ketamine analogs could establish these as effective treatments for pain, depression, anxiety, and related disorders.
Competitive Advantages
Ketamine analogs including (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects.

Request More Info

Licensing Contact: